



Biotech Daily

Thursday August 6, 2020

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: PATRYS UP 8%; ALTERITY DOWN 12.5%**
- * **RESMED REVENUE UP 13% TO \$4.1b, PROFIT UP 32% TO \$963m**
- * **ALCIDION: NHS TO USE SMARTPAGE FOR IN-HOUSE COMMUNICATION**
- * **IMUGENE PRE-IND FDA MEETING ON VAXINIA (CF33) PATHWAY**
- * **NEUREN PLAN RAISES \$200k OF HOPED-FOR \$3m; TOTAL \$20.2m**
- * **PLATINUM DILUTED TO 16% IN AMPLIA**
- * **BLUEFLAG, ALLAN MOSS DILUTED TO 7% OF AMPLIA**
- * **TOTAL BRAIN APPOINTS MELISSA FRIESWICK 'CHIEF REVENUE OFFICER'**

MARKET REPORT

The Australian stock market was up 0.68 percent on Thursday August 6, 2020, with the ASX200 up 40.9 points to 6,042.2 points.

Eighteen of the Biotech Daily Top 40 stocks were up, 14 fell and eight traded unchanged. All three Big Caps fell.

Patrys was the best, up 0.1 cents or 8.3 percent to 1.3 cents, with 6.4 million shares traded.

Kazia climbed 7.7 percent; Actinogen and Compumedics improved more than four percent; Amplia and Nova were up more than three percent; Clinuvel, Cynata, Pharmaxis, Pro Medicus, Telix and Universal Biosensors rose two percent or more; with Antisense, Avita, Dimerix, Imugene, Nanosonics and Opthea up by more than one percent.

Alterity led the falls, down 0.8 cents or 12.5 percent to 5.6 cents, with 41.0 million shares traded.

Proteomics and Resmed fell more than seven percent; LBT lost 3.2 percent; Genetic Signatures, Medical Developments, Osprey, Uscom and Volpara shed more than two percent; Cyclopharm, Impedimed, Next Science and Polynovo were down more than one percent; with Cochlear, CSL, Paradigm and Starpharma down less than one percent.

RESMED INC

Resmed says revenue for the 12 months to June 30, 2019 was up 13.4 percent to \$US2,957,000,000 (\$A4,109,960,000) with net profit after tax up 31.6 percent to \$US692,800,000 (\$A962,911,000).

Resmed said the revenue came from sales of its anti-snoring and sleep apnoea devices, as well as its ventilators, ventilation mask systems and remote ventilation monitoring and assistance software for Covid-19.

The company provided both US generally accepted accounting principles (GAAP) and non-GAAP data, saying it “uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods ... [and] believes this information provides investors better insights”.

This report quotes the non-GAAP data.

Resmed said that cash and cash equivalents at June 30, 2020 was \$US463,156,000 compared to \$US147,128,000 at June 30, 2019, with non-GAAP diluted earnings per share up 30.8 percent to \$US4.76.

The company said it would pay a dividend of 39 US cents a share for the three months to June 30, for the record date of August 20 and to be paid on September 24, 2020.

Resmed chief executive officer Mick Farrell said that “looking ahead, we are confident in our ability to navigate through the ongoing challenging clinical and economic environment to deliver for all our stakeholders”.

“Sleep labs and physician practices are reopening across many geographies, and we’re seeing accelerated adoption of digital health solutions which supports our long-term strategy,” Mr Farrell said.

Resmed fell \$2.07 or 7.4 percent to \$25.88 with 4.7 million shares traded.

ALCIDION GROUP

Alcidion says the UK National Health Service will use its Smartpage messaging system to replace pagers as a line of non-emergency communication.

Alcidion said the NHSX, an NHS program for digital health and social care transformation, had awarded the company a place on its GBP3 million (\$A5.5 million) Clinical Communications Procurement Framework”.

The company said the framework followed an order from the UK Secretary for Health and Social Care Matt Hancock for the removal of pagers from the NHS for non-emergency communications by the end of 2021.

Alcidion said that a complex mix of pagers, legacy phones and whiteboards were a cause of communication delays or errors in many hospitals today which lead to longer waiting times, delayed or missed care and lack of visibility into staff workloads.

The company said Smartpage allowed professionals to message text and photos with guaranteed message delivery and provided a “real-time” organization-wide oversight of operations.

Alcidion UK general manager Lynette Ousby said the NHSX had “shown a commitment through this framework to accelerate the spread of modern technologies in the health service that can help healthcare professionals communicate effectively during the busiest of times”.

“The inclusion of Smartpage on this framework is an important independent validation for Alcidion’s Smartpage product,” Ms Ousby said.

“We look forward to helping [NHS] trusts modernise their communications tools through a framework in a way that is affordable and straightforward,” Ms Ousby said.

Alcidion was unchanged at 13.5 cents.

IMUGENE

Imugene says the US Food and Drug Administration has advised the development plan for its Vaxinia, or CF33, oncolytic virotherapy for solid tumors.

Imugene chief executive officer Leslie Chong said the pre-investigational new drug meeting with the FDA provided “a clear roadmap for a successful IND submission and clinical development of Vaxinia”.

The company said it received FDA guidance for its phase I Vaxinia study design, including the combination with immune checkpoint inhibitors, the proposed patient population, safety monitoring plan, and strategy for evaluating drug exposure.

Imugene said that given the uncertainty in the Covid-19 era, it would be “flexible in identifying regulatory pathways” and was pursuing a regulatory pathway in Australia.

Imugene was up 0.1 cents or 1.8 percent to 5.7 cents with 29.2 million shares traded.

NEUREN PHARMACEUTICALS

Neuren says its share plan has raised \$200,000 of a hoped-for \$3 million.

In June, Neuren said it raised \$20 million in a placement at \$1.40 a share and hoped to raise a further \$3 million through a share plan (BD: Jun 29, 2020).

Today, Neuren chief executive officer Jon Pilcher said the capital raising would fund phase II trials of NNZ-2591 for Phelan-McDermid, Angelman and Pitt Hopkins syndromes.

Neuren was unchanged at \$1.30.

AMPLIA THERAPEUTICS

Sydney’s Platinum Investment Management says its 17,169,000 share-holding in Amplia has been diluted from 19.89 percent to 16.15 percent.

Last week, Amplia said that following its \$2 million institutional rights offer, it had applications for \$1.83 million in its underwritten retail rights offer at 10 cents and the \$170,000 shortfall would be placed by underwriter Taylor Collison (BD: Jul 30, 2020).

Amplia was up half a cent or 3.85 percent to 13.5 cents.

AMPLIA THERAPEUTICS

The Sydney-based Blueflag Holdings says its 7,500,000 shares in Amplia have been diluted from 8.69 percent to 7.08 percent (see above).

The substantial shareholder noticed was signed by Blueflag director Allan Moss, the former managing-director of Macquarie Group.

TOTAL BRAIN

Total Brain says it has appointed Melissa Frieswick as “chief revenue officer”, effective immediately.

Total Brain told Biotech Daily that a chief revenue officer was effectively head of sales.

Total Brain said that previously Ms Frieswick was Maven digital healthcare chief revenue officer and worked for companies in the healthcare industry including Virgin Group.

Total Brain was up five cents or 13.0 percent to 43.5 cents.